Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
102 hedge funds and large institutions have $693M invested in Eidos Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 10 closing their positions.
230% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 10
190% more call options, than puts
Call options by funds: $16.5M | Put options by funds: $5.7M
69% more capital invested
Capital invested by funds: $411M → $693M (+$282M)
29% more funds holding
Funds holding: 79 → 102 (+23)
11% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$18.3M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$16.8M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$10.8M |
| 4 |
Holocene Advisors
New York
|
+$8.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$11M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$8.14M |
| 3 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$5.11M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$4.66M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.54M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
101
Valeo Financial Advisors
Carmel,
Indiana
| $4K | +$3.07K | +62 | New |
|
102
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$885K | -17,876 | -100% |
|
|
OAC
103
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$5.11M | -142,000 | Closed |
|
|
PHS
104
PFM Health Sciences
San Francisco,
California
| – | -$4.54M | -126,181 | Closed |
|
|
EU
105
Emory University
Atlanta,
Georgia
| – | -$2.44M | -67,753 | Closed |
|
106
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.14M | -23,003 | Closed |
|
|
HF
107
HRT Financial
New York
| – | -$577K | -16,047 | Closed |
|
|
ECM
108
ExodusPoint Capital Management
New York
| – | -$359K | -9,989 | Closed |
|
|
PP
109
Paloma Partners
Greenwich,
Connecticut
| – | -$264K | -7,336 | Closed |
|
|
PIM
110
Partner Investment Management
San Francisco,
California
| – | -$22K | -607 | Closed |
|
|
TRCT
111
Tower Research Capital (TRC)
New York
| – | -$18K | -512 | Closed |
|
112
UBS AM
Chicago,
Illinois
| – | -$2.3K | -64 | Closed |
|
EIDX Hedge Fund Activity: Q4 2019 in Review
102 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q4 2019, worth a combined $693M — up 69% from $411M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new EIDX positions and 10 closed out — a net gain of 23 holders — while 30 added to existing stakes and 27 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, opening a new position worth an estimated $18.3M. The largest seller was Redmile Group, cutting an estimated $11M.
- 102 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q4 2019, up from 79 in Q3 2019.
- Funds reported $693M of Eidos Therapeutics, Inc. Common Stock stock for Q4 2019, up 69% quarter-over-quarter.
- 33 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q4 2019 and 10 closed out, a net change of +23 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q4 2019 was Gilder Gagnon Howe & Co, an estimated $18.3M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q4 2019 was Redmile Group, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2019.